In recent years, the focus of NSCLC treatment has shifted to identifying and targeting specific tumor mutations, leading to individualized therapy. Targeting the epidermal growth factor receptor (EGFR) has played a central role in advancing NSCLC research, treatment, and patient outcomes over the last several years. Despite an initial benefit from EGFR-targeted TKIs, a majority of patients treated with these agents experience cancer recurrence due to acquired drug resistance. This unavoidable challenge has led to extensive research on resistance mechanisms and other tumor mutations that could be targeted. Currently, there are several novel agents undergoing clinical trials that target different receptor tyrosine kinases (RTKs), intracellular signaling pathways, and poly ADP ribose polymerase (PARP) proteins to improve the management of advanced NSCLC. This satellite symposium, Individualizing Therapy for Patients with Lung Cancer - What does the Future Hold?, held during the 19th Annual Perspectives in Thoracic Oncology meeting aims to provide healthcare professionals a comprehensive review of the novel targeting agents in early clinical development for lung cancer.
In this presentation, Dr. Corey J. Langer discusses the targeting of PARP proteins and intracellular signaling components.
Earn accreditation for this activity at the following location:
[ Ссылка ]
© 2014 Imedex, LLC.
